99 related articles for article (PubMed ID: 7654038)
1. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients.
Katsaros D; Theillet C; Zola P; Louason G; Sanfilippo B; Isaia E; Arisio R; Giardina G; Sismondi P
Anticancer Res; 1995; 15(4):1501-10. PubMed ID: 7654038
[TBL] [Abstract][Full Text] [Related]
2. Amplifications of proto-oncogenes in ovarian carcinoma.
Bian M; Fan Q; Huang S; Ma J; Lang J
Chin Med J (Engl); 1995 Nov; 108(11):844-8. PubMed ID: 8585978
[TBL] [Abstract][Full Text] [Related]
3. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
Schuyer M; van der Burg ME; Henzen-Logmans SC; Fieret JH; Klijn JG; Look MP; Foekens JA; Stoter G; Berns EM
Br J Cancer; 2001 Nov; 85(9):1359-67. PubMed ID: 11720475
[TBL] [Abstract][Full Text] [Related]
5. Oncogene patterns in breast and ovarian carcinomas.
Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
[TBL] [Abstract][Full Text] [Related]
6. Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas.
Fan QB; Bian ML; Huang SZ; Lang JH; Ma J; Liu WS; Xu XY
Chin Med J (Engl); 1994 Aug; 107(8):589-93. PubMed ID: 7805442
[TBL] [Abstract][Full Text] [Related]
7. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
Jamieson S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
[TBL] [Abstract][Full Text] [Related]
8. [c-erbB2 gene amplification in human primary epithelial ovarian cancer and its clinical significance].
Yang H; Zhang G; Xu K
Zhonghua Zhong Liu Za Zhi; 1998 Sep; 20(5):367-70. PubMed ID: 10921034
[TBL] [Abstract][Full Text] [Related]
9. [Amplification of proto-oncogenes C-myc, C-N-ras, C-Ki-ras, C-erbB2 in ovarian carcinoma].
Bian M; Fan Q; Huang S
Zhonghua Fu Chan Ke Za Zhi; 1995 Jul; 30(7):406-9. PubMed ID: 7587576
[TBL] [Abstract][Full Text] [Related]
10. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
11. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC
Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444
[TBL] [Abstract][Full Text] [Related]
12. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
13. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis.
Scorilas A; Trangas T; Yotis J; Pateras C; Talieri M
Br J Cancer; 1999 Dec; 81(8):1385-91. PubMed ID: 10604737
[TBL] [Abstract][Full Text] [Related]
14. p53, c-erbB-2 and p21ras expression in tumor effusion cells of patients with histopathologically different ovarian neoplasms.
Harłozińska A; Bar JK; Sobańska E; Goluda M
Anticancer Res; 1997; 17(5A):3545-52. PubMed ID: 9413200
[TBL] [Abstract][Full Text] [Related]
15. [Molecular biology of ovarian cancer].
Tanaka K
Gan To Kagaku Ryoho; 1999 Dec; 26(14):2162-7. PubMed ID: 10635299
[TBL] [Abstract][Full Text] [Related]
16. [The relation between prognosis and amplification of the c-erB-2 (HER-2/neu) proto-oncogene in ovarian carcinomas].
Fan QB; Bian ML; Huang SZ
Zhonghua Yi Xue Za Zhi; 1994 Nov; 74(11):683-5, 710. PubMed ID: 7866905
[TBL] [Abstract][Full Text] [Related]
17. [Genetic alterations in the genesis and development of ovarian cancer].
Okamoto A; Yokoyama S; Terashima Y
Gan To Kagaku Ryoho; 1992 Oct; 19(12):1971-6. PubMed ID: 1358031
[TBL] [Abstract][Full Text] [Related]
18. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
19. Overexpression and amplification of c-myc and c-Ha-ras oncogenes in pleomorphic salivary adenoma.
Xue H; Situ ZQ; Wang CJ; Wu JZ
Chin Med J (Engl); 1993 Jan; 106(1):22-5. PubMed ID: 8389270
[TBL] [Abstract][Full Text] [Related]
20. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients.
Scorilas A; Yotis J; Stravolemos K; Gouriotis D; Keramopoulos A; Ampela K; Talieri M; Trangas T
Anticancer Res; 1995; 15(4):1543-7. PubMed ID: 7654043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
